SIRT4 and hepatocellular carcinoma: Serving as a co-regulator of SIRT4, SET8 sustains the survival of HCC cells both in vitro and in vivo by promoting glucose metabolism and thereby could be a potential therapeutic target in treatment of the HCC patients.